Breast cancers frequently harbor mutations in the phosphoinositide 3-kinase (PI3K)/mechanistic target of Rapamycin (mTOR) pathway with activating mutations in PIK3CA or loss of function mutations in PTEN, together occurring in over 70% of cases [1]. This evidence concerns the gene PIK3CA and breast cancer.